ArticleCrohn's & colitis 3602021

The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients.

Nabeel Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.